ProQR Therapeutics shares surge 11.11% intraday as company announces April 8 investor event and analysis highlights 548% upside potential.

ProQR Therapeutics surged 11.11% intraday, driven by two key developments: first, the company announced on March 25 a virtual investor and analyst event on April 8 to showcase its RNA editing pipeline beyond AX-0810 and disclose the primary indication for AX-0810 and new projects with upcoming clinical data readouts. Second, on March 29, an analysis highlighted that based on its Axiomer™ RNA editing platform and pipeline, ProQR has potential for a 548% upside.